Edwards Lifesciences Corporation

$92.01

-2.57%

Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a Health Care company listed on NEW YORK STOCK EXCHANGE, INC..

Industry

Health Care

Exchange

NEW YORK STOCK EXCHANGE, INC.

Market Cap

$53.0B

P/E Ratio

52.8

Cash on Hand

$4.2B(positive)

Shares Outstanding

576.4M shares

Currency

USD

Visit website →

About

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.

via Wikipedia →

Earnings (EPS)

QuarterEPS EstimateEPS Actual

Q2 2026$0.76$0.78

Q1 2026$0.75$0.78

Q4 2025$0.64$0.58

Q3 2025$0.61$0.67

Financial Highlights

The basics, explained simply — no finance degree required.

52-Week Range

$74.66 – $96.29

The lowest and highest price this stock has traded at over the past year.

Profit Margin

15.4%

How much of every $1 in sales turns into actual profit. Higher generally means a healthier business.

Revenue Growth

+14.6%

How much the company's sales grew compared to a year ago.

Volatility (Beta)

0.82

How much this stock tends to swing compared to the overall market. Above 1 means it typically moves more than the market (higher risk, higher potential reward); below 1 means it's historically calmer.

Loading Company intelligence…

Analyst Insights

Analyst Consensus

Buy

Based on 38 analysts

Next Earnings

Nov 4, 2026

Earnings calendar →

Similar Companies

ABT ISRG SYK BSX BDX

Insider Activity

Recent buys and sells by company executives and directors — publicly disclosed, as required by law.

Lippis Daniel J.

Oct 8, 2026 • $72.68/share

Bought 619

Lippis Daniel J.

Oct 8, 2026 • $85.65/share

Sold 619

Lippis Daniel J.

Oct 8, 2026

Sold 619

Markowitz Wayne

Sep 14, 2026 • $84.37/share

Sold 568

Dahl Andrew M.

Sep 13, 2026 • $84.37/share

Sold 253

Lippis Daniel J.

Sep 11, 2026 • $72.68/share

Bought 619

Latest SEC Filings

Loading filings…

← Back to homepage

Loading… fetching the latest figures.

Edwards Lifesciences Corporation

$92.01

-2.57%

Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a Health Care company listed on NEW YORK STOCK EXCHANGE, INC..

Industry

Health Care

Exchange

NEW YORK STOCK EXCHANGE, INC.

Market Cap

$53.0B

P/E Ratio

52.8

Cash on Hand

$4.2B(positive)

Shares Outstanding

576.4M shares

Currency

USD

Visit website →

About

via Wikipedia →

Earnings (EPS)

QuarterEPS EstimateEPS Actual

Q2 2026$0.76$0.78

Q1 2026$0.75$0.78

Q4 2025$0.64$0.58

Q3 2025$0.61$0.67

Financial Highlights

The basics, explained simply — no finance degree required.

52-Week Range

$74.66 – $96.29

The lowest and highest price this stock has traded at over the past year.

Profit Margin

15.4%

How much of every $1 in sales turns into actual profit. Higher generally means a healthier business.

Revenue Growth

+14.6%

How much the company's sales grew compared to a year ago.

Volatility (Beta)

0.82

Company Intelligence

Annual figures from the company's own SEC filings. Tap any number to open the filing it came from.

Revenue

Growth = this year ÷ prior year − 1

Dec 2025: $6.1B+11.5%
Dec 2024: $5.4B+8.6%
Dec 2023: $5.0B+12.2%
Dec 2022: $4.5B-14.7%

Operating income

Margin = operating income ÷ revenue

Dec 2025: $1.3B20.8% margin
Dec 2024: $1.4B25.3% margin
Dec 2023: $1.3B26.1% margin
Dec 2022: $1.5B33.6% margin

Net income

Margin = net income ÷ revenue

Dec 2025: $1.1B17.7% margin
Dec 2024: $4.2B76.7% margin
Dec 2023: $1.4B28.0% margin
Dec 2022: $1.5B34.1% margin

Operating cash flow

Cash the business generated, vs net income above

Dec 2025: $1.6B
Dec 2024: $542M
Dec 2023: $896M
Dec 2022: $1.2B

Cash vs long-term debt

Cash − long-term debt. Excludes short-term borrowings and leases

Dec 2025: —
Dec 2024: $2.4B$3.0B cash · $598M debt
Dec 2023: $535M$1.1B cash · $597M debt
Dec 2022: $173M$769M cash · $596M debt

Shares (weighted avg.)

Change = this year ÷ prior year − 1

Dec 2025: 585M-2.2%
Dec 2024: 598M-1.5%
Dec 2023: 607M-2.0%
Dec 2022: 619M-0.7%

Fiscal year ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022
RevenueGrowth = this year ÷ prior year − 1	$6.1B+11.5%	$5.4B+8.6%	$5.0B+12.2%	$4.5B-14.7%
Operating incomeMargin = operating income ÷ revenue	$1.3B20.8% margin	$1.4B25.3% margin	$1.3B26.1% margin	$1.5B33.6% margin
Net incomeMargin = net income ÷ revenue	$1.1B17.7% margin	$4.2B76.7% margin	$1.4B28.0% margin	$1.5B34.1% margin
Operating cash flowCash the business generated, vs net income above	$1.6B	$542M	$896M	$1.2B
Cash vs long-term debtCash − long-term debt. Excludes short-term borrowings and leases	—	$2.4B$3.0B cash · $598M debt	$535M$1.1B cash · $597M debt	$173M$769M cash · $596M debt
Shares (weighted avg.)Change = this year ÷ prior year − 1	585M-2.2%	598M-1.5%	607M-2.0%	619M-0.7%

What the numbers show

Operating cash flow was below net income in 3 of 4 profitable years shown (Dec 2024, Dec 2023, Dec 2022).
Revenue fell in 1 of the last 4 fiscal years shown (Dec 2022).
Operating margin was 33.6% in Dec 2022 and 20.8% in Dec 2025.
Weighted average shares decreased 5.5% between Dec 2022 and Dec 2025.

Worth a closer look

Automatic checks on the figures above. A flag is a pattern to investigate, not a finding of wrongdoing, and each one lists ordinary explanations for it.

Operating margin shrinking

Operating margin fell from 26.1% in Dec 2023 to 25.3% in Dec 2024 and 20.8% in Dec 2025.

Operating income	Dec 2025	$1.3B
Revenue	Dec 2025	$6.1B
Operating income	Dec 2024	$1.4B
Revenue	Dec 2024	$5.4B
Operating income	Dec 2023	$1.3B
Revenue	Dec 2023	$5.0B

How it's calculated: Operating margin = operating income ÷ revenue, for each year.

Rule: Operating margin lower in each of the last two years, down 3 percentage points or more in total.

Why it matters, and ordinary explanations

Why it can matter: A margin that keeps shrinking can mean costs are rising faster than prices, or that the company is losing pricing power.

Common innocent explanations: Deliberate investment in growth, a shift in the mix of products, or one-off charges that depress a single year.

See every flagged company in Market Watch →

Rules checked

Revenue up, operating cash flow down — not triggered. Revenue up 5% or more in the latest year while operating cash flow fell 10% or more.
Profit not matched by cash — not triggered. Net income positive, but operating cash flow below 70% of net income in each of the last two fiscal years.
Receivables growing faster than revenue — not run. Not enough comparable annual figures reported to run this check.
Share count rising — not triggered. Weighted average shares up 5% or more in a year, or 10% or more over three years.
Operating margin shrinking — flagged. Operating margin lower in each of the last two years, down 3 percentage points or more in total.

Source: SEC EDGAR annual reports (Form 10-K), latest filed 2026-02-25. If a company later restates a year, the most recent filing is used. Dashes mean the company did not report that line in a form we could read. For information only, not investment advice.

Loading Company intelligence…

Analyst Insights

Analyst Consensus

Buy

Based on 38 analysts

Next Earnings

Nov 4, 2026

Earnings calendar →

Similar Companies

ABT ISRG SYK BSX BDX

Insider Activity

Recent buys and sells by company executives and directors — publicly disclosed, as required by law.

Lippis Daniel J.

Oct 8, 2026 • $72.68/share

Bought 619

Lippis Daniel J.

Oct 8, 2026 • $85.65/share

Sold 619

Lippis Daniel J.

Oct 8, 2026

Sold 619

Markowitz Wayne

Sep 14, 2026 • $84.37/share

Sold 568

Dahl Andrew M.

Sep 13, 2026 • $84.37/share

Sold 253

Lippis Daniel J.

Sep 11, 2026 • $72.68/share

Bought 619

Latest SEC Filings

Loading filings…

← Back to homepage